Clinical Trials
8 trialsNCT01676818 2025-11-06
Eribulin Mesylate in Treating Patients With Advanced or Recurrent Cervical Cancer
University of Southern California
Phase 2 Completed
NCT02419495 2025-06-04
Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT05238831 2024-01-23
SMMART Adaptive Clinical Treatment (ACT) Trial
OHSU Knight Cancer Institute
Phase EARLY_PHASE1 Withdrawn
NCT03430518 2020-08-05
Durvalumab and Eribulin in Her2-negative Metastatic Breast Cancer and Recurrent Ovarian Cancer
Icahn School of Medicine at Mount Sinai
Phase 1 Completed
NCT00410553 2018-10-03
Eribulin Mesylate and Gemcitabine Hydrochloride in Treating Patients With Metastatic Solid Tumors or Solid Tumors That Cannot be Removed by Surgery
National Cancer Institute (NCI)
Phase 1 Completed
NCT02014337 2018-01-17
Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors
Corcept Therapeutics
Phase 1 Completed
NCT00334893 2017-11-29
Eribulin Mesylate in Treating Patients With Recurrent Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT03032614 2017-10-10
Combination of Carboplatin, Eribulin and Veliparib in Stage IV Cancer Patients
The University of Texas Health Science Center at San Antonio
Phase 2 Withdrawn